Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H

INTRODUCTION: Ixekizumab, a selective interleukin-17A antagonist, was compared with adalimumab in the SPIRIT-H2H study (NCT03151551) in patients with psoriatic arthritis (PsA) and concomitant psoriasis. This post hoc analysis reports outcomes to week 52 in patients from SPIRIT-H2H, stratified by bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristensen, Lars-Erik, Okada, Masato, Tillett, William, Leage, Soyi Liu, El Baou, Celine, Sapin, Christophe, Bradley, Andrew J., Meszaros, Gabriella, Dutz, Jan P., de Vlam, Kurt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814242/
https://www.ncbi.nlm.nih.gov/pubmed/34709605
http://dx.doi.org/10.1007/s40744-021-00388-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814242/
https://www.ncbi.nlm.nih.gov/pubmed/34709605
http://dx.doi.org/10.1007/s40744-021-00388-8

Ejemplares similares